Clinical Trials | Adults with Acute Myeloid Leukemia (AML) are Invited to Participate in a Research Study

The UVA Cancer Center is doing a study for people with acute myeloid leukemia (AML). This study is for people whose earlier treatment did not work, or it worked for a while and then the cancer came back. The goal of the study is to see if a new drug called C6 Ceramide NanoLiposome (CNL) is safe for people with AML, what dose works best, and how well it might help them. People in the study will get the CNL drug twice a week through an IV (a tube in a vein). They will keep getting it as long as their AML does not get worse. Blood will be taken before, and sometimes after, the first 8 doses to see how the drug moves through and affects the body. After the first cycle (8 doses over 4 weeks) and the second cycle, people will have a bone marrow test to check their AML. After that, bone marrow tests will be done as part of standard care. During the study, people will fill out short questionnaires to share how they are feeling. After treatment ends, the study team will keep in touch to see how people are doing. Some follow-up visits can be done by phone or email. Any tests done only for research will be free and not billed to people in the study or their insurance. More information may be found at clinicaltrials.gov: clinicaltrials.gov - NCT04716452 or by contacting [email protected].